DiaSorin stock: Valuation sets DiaSorin stock at a 23.99 price-to-earnings ratio

Published on 10/19/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Constant-rate revenue grew 4.00 percent in second-quarter 2026. DiaSorin stock costs EUR 77.03 on October 19, 2026, minus 0.27 percent versus Borsa close.

Valuation and operating figures

On October 19, 2026, DiaSorin's price-to-earnings ratio stood at 23.99.
Constant-rate revenue grew 4.00 percent in second-quarter 2026.
DiaSorin stock costs EUR 77.03 at Lang & Schwarz on October 19, 2026 at 4:45 p.m. CEST, minus 0.27 percent versus the Borsa Italiana close of October 16, 2026.
Market capitalization stood at EUR 3.8 billion on October 19, 2026.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

Valuation puts DiaSorin's price-to-earnings ratio at 23.99 and its market capitalization at EUR 3.8 billion on October 19, 2026. The company remains positioned in healthcare diagnostics, with Borsa Italiana describing its business as the development and manufacture of in vitro diagnostic reagents in its company profile. At Lang & Schwarz, DiaSorin was trading at EUR 77.03 on October 19, 2026 at 4:45 p.m. CEST, minus 0.27 percent versus the Borsa Italiana close of October 16, 2026 (EUR 77.24).

Second-quarter revenue returned to growth

DiaSorin's second-quarter 2026 revenue grew 4.00 percent at constant exchange rates, according to Yahoo Finance. The same transcript said immunodiagnostics grew 4.00 percent, life technology and genomics increased 7.00 percent, and the company expected to reach 600 hospitals by the end of 2026.

DiaSorin's first-half 2026 results call took place on July 31, 2026. Management said the full-year outlook called for revenue growth of 5.00 to 6.00 percent at constant exchange rates and an adjusted EBITDA margin of 32.00 to 33.00 percent, while first-half revenue totaled EUR 602 million, according to Yahoo Finance.

Stock sits below its yearly high

The Lang & Schwarz price was EUR 2.69 below DiaSorin's 52-week high of EUR 79.72 and EUR 24.69 above its 52-week low of EUR 52.34 on October 19, 2026. That places the stock 3.37 percent below the high and 47.17 percent above the low. The finance quote showed 21,364 shares traded against an average volume of 193,922.

Valuation and peer comparison

The price-to-earnings ratio was 23.99 and the trailing dividend yield was 2.00 percent on October 19, 2026. DiaSorin's market capitalization was EUR 3.8 billion.

Comparison with peers

DiaSorin (Borsa Italiana, EUR): minus 0.27 percent, P/E 23.99, market capitalization EUR 3.8 billion.

bioMérieux (Euronext Paris, EUR): minus 0.57 percent, P/E 22.27, market capitalization EUR 10.2 billion.

Qiagen (NYSE, USD): plus 0.26 percent, P/E 23.68, market capitalization USD 9.5 billion.

Trading position and next steps

The Borsa Italiana listing identifies DiaSorin under ticker DIA.MI and places the company in the FTSE MIB. The market picture combines a small decline against the October 16 close with a 23.99 price-to-earnings ratio and a second-quarter return to growth.

DiaSorin was trading at EUR 77.03 at Lang & Schwarz on October 19, 2026 at 4:45 p.m. CEST, minus 0.27 percent versus the Borsa Italiana close of October 16, 2026 (EUR 77.24). The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.